Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Sponsor
Sichuan Cancer Hospital and Research Institute
Study ID
NCT04133337
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Lung Diseases
  • Neoplasms
  • Non-small-cell Lung Cancer
  • Respiratory Tract Diseases
  • Thoracic Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib Mesylate Tablets
  • SHR-1210 — DRUG
    Camrelizumab for Injection

Study Details

The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.

Key Dates

First listed
Oct 21, 2019
Start date
Nov 1, 2019
Status verified
Oct 2019
Primary completion
Jun 1, 2020
Completion
Jun 30, 2021

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib Combined With SHR-1210 Injection
    * Drugs:Apatinib Apatinib mesylate tablets 250 mg qd po, discontinued one week before surgery. * Drugs: SHR-1210 SHR-1210 injection 200mg (5mL), ivgtt, q2w, 3 cycles, each time 20-60min completed infusion. * Surgery: The patient underwent imaging examinations within 7 days prior to surgery, including chest CT and related metastatic examinations. The patient underwent surgery 7-8 weeks after the first dose.

Primary Outcome Measure

Major pathologic response rate(MPR)(<10% viable tumor cells) [ Time Frame: At time of surgery ]

Central Contacts

Related Studies